

Janet M Shipley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/836874/publications.pdf>

Version: 2024-02-01

150
papers

19,318
citations

41344

49
h-index

11607

135
g-index

157
all docs

157
docs citations

157
times ranked

23930
citing authors

#	ARTICLE	IF	CITATIONS
1	FGF7â€™FGFR2 autocrine signaling increases growth and chemoresistance of fusionâ€™positive rhabdomyosarcomas. <i>Molecular Oncology</i> , 2022, 16, 1272-1289.	4.6	7
2	Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe. <i>European Journal of Cancer</i> , 2022, 172, 367-386.	2.8	19
3	Pathology of childhood rhabdomyosarcoma: A consensus opinion document from the Children's Oncology Group, European Paediatric Soft Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28798.	1.5	38
4	Hypoxia and its therapeutic possibilities in paediatric cancers. <i>British Journal of Cancer</i> , 2021, 124, 539-551.	6.4	28
5	Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response. <i>Cancer Research</i> , 2021, 81, 1667-1680.	0.9	32
6	Role for the Histone Demethylase KDM4B in Rhabdomyosarcoma via CDK6 and CCNA2: Compensation by KDM4A and Apoptotic Response of Targeting Both KDM4B and KDM4A. <i>Cancers</i> , 2021, 13, 1734.	3.7	6
7	Non-parameningeal head and neck rhabdomyosarcoma in children, adolescents, and young adults: Experience of the European paediatric Soft tissue sarcoma Study Group (EpSSG) â€™ RMS2005 study. <i>European Journal of Cancer</i> , 2021, 151, 84-93.	2.8	21
8	Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 2859-2871.	1.6	101
9	Experimental Models. <i>Pediatric Oncology</i> , 2021, , 129-147.	0.5	0
10	Aurora A Kinase Inhibition Destabilizes PAX3-FOXO1 and MYCN and Synergizes with Navitoclax to Induce Rhabdomyosarcoma Cell Death. <i>Cancer Research</i> , 2020, 80, 832-842.	0.9	31
11	Genomic landscape of platinum resistant and sensitive testicular cancers. <i>Nature Communications</i> , 2020, 11, 2189.	12.8	43
12	Desmoplastic small round cell tumor (DSRCT): emerging therapeutic targets and future directions for potential therapies. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 281-285.	3.4	11
13	Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1659-1670.	2.5	13
14	Epigenetic Targets in Synovial Sarcoma: A Mini-Review. <i>Frontiers in Oncology</i> , 2019, 9, 1078.	2.8	22
15	A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations. <i>European Journal of Cancer</i> , 2019, 121, 224-235.	2.8	44
16	Catalytic inhibition of KDM1A in Ewing sarcoma is insufficient as a therapeutic strategy. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27888.	1.5	19
17	Insights into pediatric rhabdomyosarcoma research: Challenges and goals. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27869.	1.5	57
18	Vgll3 operates via Tead1, Tead3 and Tead4 to influence myogenesis in skeletal muscle. <i>Journal of Cell Science</i> , 2019, 132, .	2.0	48

#	ARTICLE	IF	CITATIONS
19	A Perspective on Polo-Like Kinase-1 Inhibition for the Treatment of Rhabdomyosarcomas. <i>Frontiers in Oncology</i> , 2019, 9, 1271.	2.8	12
20	Rhabdomyosarcoma. <i>Nature Reviews Disease Primers</i> , 2019, 5, 1.	30.5	619
21	The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells. <i>BMC Cancer</i> , 2018, 18, 217.	2.6	25
22	IGF1R signalling in testicular germ cell tumour cells impacts on cell survival and acquired cisplatin resistance. <i>Journal of Pathology</i> , 2018, 244, 242-253.	4.5	24
23	Fusion status in patients with lymph node-positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). <i>Cancer</i> , 2018, 124, 3201-3209.	4.1	51
24	Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 19, 1061-1071.	10.7	137
25	Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness. <i>Scientific Reports</i> , 2018, 8, 10614.	3.3	13
26	Targeted resequencing of pediatric rhabdomyosarcoma: report from the Children's Oncology Group, the Children's Cancer and Leukaemia Group, The Institute of Cancer Research UK, and the National Cancer Institute.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10515-10515.	1.6	9
27	Abstract 2975: Synthetic lethality in synovial sarcoma: SS18-SSX fusions and DNA damage response (DDR) inhibitors. , 2018, , .		0
28	Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor. <i>Nature Genetics</i> , 2017, 49, 1133-1140.	21.4	120
29	Fusion gene addiction: can tumours be forced to give up the habit?. <i>Journal of Pathology</i> , 2017, 242, 263-266.	4.5	4
30	Impact of fusion gene status versus histology on risk-stratification for rhabdomyosarcoma: Retrospective analyses of patients on UK trials. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26386.	1.5	21
31	MicroRNA and gene co-expression networks characterize biological and clinical behavior of rhabdomyosarcomas. <i>Cancer Letters</i> , 2017, 385, 251-260.	7.2	30
32	ATR Is a Therapeutic Target in Synovial Sarcoma. <i>Cancer Research</i> , 2017, 77, 7014-7026.	0.9	43
33	Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent. <i>Oncotarget</i> , 2017, 8, 71371-71384.	1.8	85
34	Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours. <i>Oncotarget</i> , 2017, 8, 112036-112050.	1.8	16
35	Defining a New Prognostic Index for Stage I Nonseminomatous Germ Cell Tumors Using CXCL12 Expression and Proportion of Embryonal Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 1265-1273.	7.0	23
36	Endosialin expression in soft tissue sarcoma as a potential marker of undifferentiated mesenchymal cells. <i>British Journal of Cancer</i> , 2016, 115, 473-479.	6.4	23

#	ARTICLE	IF	CITATIONS
37	The Hippo effector <i>TAZ</i> (<i>WWTR1</i>) transforms myoblasts and <i>TAZ</i> abundance is associated with reduced survival in embryonal rhabdomyosarcoma. <i>Journal of Pathology</i> , 2016, 240, 3-14.	4.5	40
38	Genome-wide methylation analysis identifies genes silenced in non-seminoma cell lines. <i>Npj Genomic Medicine</i> , 2016, 1, 15009.	3.8	6
39	The genomic landscape of testicular germ cell tumours: from susceptibility to treatment. <i>Nature Reviews Urology</i> , 2016, 13, 409-419.	3.8	83
40	8-Substituted Pyrido[3,4- <i>d</i>]pyrimidin-4(3- <i>H</i>)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1388-1409.	6.4	83
41	Molecular biomarkers of risk in rare and other cancers – identification and impact. <i>Biochemist</i> , 2016, 38, 10-13.	0.5	0
42	Polygenic susceptibility to testicular cancer: implications for personalised health care. <i>British Journal of Cancer</i> , 2015, 113, 1512-1518.	6.4	10
43	Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumours. <i>Nature Communications</i> , 2015, 6, 5973.	12.8	161
44	Identification of four new susceptibility loci for testicular germ cell tumour. <i>Nature Communications</i> , 2015, 6, 8690.	12.8	36
45	Less Can Be More for Gene Dose and Drug Sensitivity. <i>Clinical Cancer Research</i> , 2015, 21, 4750-4752.	7.0	0
46	Clinical Application of Prognostic Gene Expression Signature in Fusion Gene–Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group. <i>Clinical Cancer Research</i> , 2015, 21, 4733-4739.	7.0	21
47	Abstract 2986: Meta-analysis of whole exome sequencing data reveals the mutational spectrum of testicular germ cell tumors. , 2015, , .		1
48	Age-related biological features of germ cell tumors. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 215-227.	2.8	24
49	Identification of ZDHHC14 as a novel human tumour suppressor gene. <i>Journal of Pathology</i> , 2014, 232, 566-577.	4.5	44
50	Rhabdomyosarcoma: Current Challenges and Their Implications for Developing Therapies. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2014, 4, a025650-a025650.	6.2	60
51	The Hippo Transducer YAP1 Transforms Activated Satellite Cells and Is a Potent Effector of Embryonal Rhabdomyosarcoma Formation. <i>Cancer Cell</i> , 2014, 26, 273-287.	16.8	152
52	Distinct Effects of Ligand-Induced PDGFR ¹ and PDGFR ² Signaling in the Human Rhabdomyosarcoma Tumor Cell and Stroma Cell Compartments. <i>Cancer Research</i> , 2013, 73, 2139-2149.	0.9	83
53	HES6 enhances the motility of alveolar rhabdomyosarcoma cells. <i>Experimental Cell Research</i> , 2013, 319, 103-112.	2.6	9
54	Identification of nine new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14. <i>Nature Genetics</i> , 2013, 45, 686-689.	21.4	149

#	ARTICLE	IF	CITATIONS
55	Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth <i>in Vitro</i> and <i>in Vivo</i> . <i>Clinical Cancer Research</i> , 2013, 19, 5940-5951.	7.0	124
56	Prediction of relapse in stage I nonseminomatous germ cell tumors (NSGCT) by CXCL12: Results from the MRC TE08 and TE22 clinical trials. <i>Journal of Clinical Oncology</i> , 2013, 31, 319-319.	1.6	4
57	Antitumor Activity of Sustained N-Myc Reduction in Rhabdomyosarcomas and Transcriptional Block by Antigen Therapy. <i>Clinical Cancer Research</i> , 2012, 18, 796-807.	7.0	74
58	Inconvenience of Convenience Cohorts Letter. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1388-1388.	2.5	3
59	Reply to S. Stegmaier et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 4040-4041.	1.6	4
60	Oncocytic Adrenal Cortical Carcinosarcoma With Pleomorphic Rhabdomyosarcomatous Metastases. <i>American Journal of Surgical Pathology</i> , 2012, 36, 470-477.	3.7	26
61	Immunohistochemical Detection of Glypican-5 in Paraffin-embedded Material. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2012, 20, 189-195.	1.2	2
62	Fluorescence In Situ Hybridization for Cancer-Related Studies. <i>Methods in Molecular Biology</i> , 2012, 878, 149-174.	0.9	7
63	<i>PAX3/FOXO1</i> Fusion Gene Status Is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk Stratification. <i>Journal of Clinical Oncology</i> , 2012, 30, 1670-1677.	1.6	297
64	Targeting the Insulin-Like Growth Factor Pathway in Rhabdomyosarcomas: Rationale and Future Perspectives. <i>Sarcoma</i> , 2011, 2011, 1-11.	1.3	45
65	Testicular germ cell tumours: predisposition genes and the male germ cell niche. <i>Nature Reviews Cancer</i> , 2011, 11, 278-288.	28.4	86
66	Minimum regions of genomic imbalance in stage I testicular embryonal carcinoma and association of 22q loss with relapse. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 186-195.	2.8	21
67	Glypican-3 is expressed in rhabdomyosarcomas but not adult spindle cell and pleomorphic sarcomas. <i>Journal of Clinical Pathology</i> , 2011, 64, 587-591.	2.0	18
68	Abstract 5343: Aberrant activation of hedgehog signaling confers a poor prognosis in embryonal and fusion gene negative alveolar rhabdomyosarcoma. , 2011, , .		0
69	Differential regulation of MAP kinase activation by a novel splice variant of human MAP kinase phosphatase-2. <i>Cellular Signalling</i> , 2010, 22, 357-365.	3.6	14
70	No evidence for V600E BRAF mutation in the seminoma cell line TCam-2. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 963-966.	2.8	6
71	A census of amplified and overexpressed human cancer genes. <i>Nature Reviews Cancer</i> , 2010, 10, 59-64.	28.4	480
72	Reply to J.R. Anderson et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e589-e590.	1.6	2

#	ARTICLE	IF	CITATIONS
73	Fusion Geneâ€“Negative Alveolar Rhabdomyosarcoma Is Clinically and Molecularly Indistinguishable From Embryonal Rhabdomyosarcoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 2151-2158.	1.6	426
74	Distinct roles for miRâ€“1 and miRâ€“133a in the proliferation and differentiation of rhabdomyosarcoma cells. <i>FASEB Journal</i> , 2010, 24, 3427-3437.	0.5	118
75	The Association of CCND1 Overexpression and Cisplatin Resistance in Testicular Germ Cell Tumors and Other Cancers. <i>American Journal of Pathology</i> , 2010, 176, 2607-2615.	3.8	89
76	Fluorescence In Situ Hybridization Analysis of Formalin Fixed Paraffin Embedded Tissues, Including Tissue Microarrays. <i>Methods in Molecular Biology</i> , 2010, 659, 51-70.	0.9	13
77	Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: An approach to identify candidate genes involved in tumor development. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 455-467.	2.8	98
78	Clinical and biological significance of CXCL12 and CXCR4 expression in adult testes and germ cell tumours of adults and adolescents. <i>Journal of Pathology</i> , 2009, 217, 94-102.	4.5	74
79	Genes, chromosomes and the development of testicular germ cell tumors of adolescents and adults. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 547-557.	2.8	48
80	DYRK1A-Dosage Imbalance Perturbs NRSF/REST Levels, Deregulating Pluripotency and Embryonic Stem Cell Fate in Down Syndrome. <i>American Journal of Human Genetics</i> , 2008, 83, 388-400.	6.2	139
81	Fluorescence and chromogenic in situ hybridization to detect genetic aberrations in formalin-fixed paraffin embedded material, including tissue microarrays. <i>Nature Protocols</i> , 2008, 3, 220-234.	12.0	50
82	Subtle genomic alterations and genomic instability revealed in diploid cancer cell lines. <i>Cancer Letters</i> , 2008, 267, 49-54.	7.2	4
83	The pattern of genomic gains in salivary gland MALT lymphomas. <i>Haematologica</i> , 2007, 92, 921-927.	3.5	25
84	Clinical relevance of molecular genetics to paediatric sarcomas. <i>Journal of Clinical Pathology</i> , 2007, 60, 1187-1194.	2.0	52
85	Role for Amplification and Expression of Glypican-5 in Rhabdomyosarcoma. <i>Cancer Research</i> , 2007, 67, 57-65.	0.9	94
86	An additional human chromosome 21 causes suppression of neural fate of pluripotent mouse embryonic stem cells in a teratoma model. <i>BMC Developmental Biology</i> , 2007, 7, 131.	2.1	17
87	The MET receptor tyrosine kinase contributes to invasive tumour growth in rhabdomyosarcomas. <i>Growth Factors</i> , 2006, 24, 197-208.	1.7	38
88	Testicular germ-cell cancer. <i>Lancet, The</i> , 2006, 367, 754-765.	18.7	370
89	Nuclear overexpression of the E2F3 transcription factor in human lung cancer. <i>Lung Cancer</i> , 2006, 54, 155-162.	2.0	78
90	No evidence for epigenetic inactivation of fumarate hydratase in leiomyomas and leiomyosarcomas. <i>Cancer Letters</i> , 2006, 235, 136-140.	7.2	20

#	ARTICLE	IF	CITATIONS
91	Comparative genomic hybridization and BUB1B mutation analyses in childhood cancers associated with mosaic variegated aneuploidy syndrome. <i>Cancer Letters</i> , 2006, 239, 234-238.	7.2	39
92	Putting the colours into chromogenic in situ hybridization (CISH). <i>Journal of Pathology</i> , 2006, 210, 1-2.	4.5	7
93	Rapid and accurate determination of MYCN copy number and 1p deletion in neuroblastoma by quantitative PCR. <i>Pediatric Blood and Cancer</i> , 2006, 46, 820-824.	1.5	9
94	Distinct comparative genomic hybridisation profiles in gastric mucosa-associated lymphoid tissue lymphomas with and without t(11;18)(q21;q21). <i>British Journal of Haematology</i> , 2006, 133, 35-42.	2.5	56
95	Nascent pre-rRNA overexpression correlates with an adverse prognosis in alveolar rhabdomyosarcoma. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 839-845.	2.8	50
96	Genomic and Expression Profiling of Human Spermatocytic Seminomas: Primary Spermatocyte as Tumorigenic Precursor and DMRT1 as Candidate Chromosome 9 Gene. <i>Cancer Research</i> , 2006, 66, 290-302.	0.9	208
97	Assessment by M-FISH of karyotypic complexity and cytogenetic evolution in bladder cancer in vitro. <i>Genes Chromosomes and Cancer</i> , 2005, 43, 315-328.	2.8	14
98	Overexpression of genes on 16q associated with cisplatin resistance of testicular germ cell tumor cell lines. <i>Genes Chromosomes and Cancer</i> , 2005, 43, 211-216.	2.8	22
99	Amplification and Overexpression of the KIT Gene Is Associated with Progression in the Seminoma Subtype of Testicular Germ Cell Tumors of Adolescents and Adults. <i>Cancer Research</i> , 2005, 65, 8085-8089.	0.9	149
100	Relationship Between MYCN Copy Number and Expression in Rhabdomyosarcomas and Correlation With Adverse Prognosis in the Alveolar Subtype. <i>Journal of Clinical Oncology</i> , 2005, 23, 880-888.	1.6	106
101	Association between Large-scale Genomic Homozygosity without Chromosomal Loss and Nonseminomatous Germ Cell Tumor Development. <i>Cancer Research</i> , 2005, 65, 9137-9141.	0.9	14
102	Activating Mutations and/or Expression Levels of Tyrosine Kinase Receptors GRB7, RAS, and BRAF in Testicular Germ Cell Tumors. <i>Neoplasia</i> , 2005, 7, 1047-1052.	5.3	70
103	A Gene Expression Signature Associated with Metastatic Outcome in Human Leiomyosarcomas. <i>Cancer Research</i> , 2004, 64, 7201-7204.	0.9	73
104	Defining minimum genomic regions of imbalance involved in testicular germ cell tumors of adolescents and adults through genome wide microarray analysis of cDNA clones. <i>Oncogene</i> , 2004, 23, 9142-9147.	5.9	38
105	Mapping of a translocation breakpoint in a Peutz-Jeghers hamartoma to the putative PJS locus at 19q13.4 and mutation analysis of candidate genes in polyp and STK11-negative PJS cases. <i>Genes Chromosomes and Cancer</i> , 2004, 41, 163-169.	2.8	29
106	Chromosomal imbalances in pleomorphic rhabdomyosarcomas and identification of the alveolar rhabdomyosarcoma-associated PAX3-FOXO1A fusion gene in one case. <i>Cancer Genetics and Cytogenetics</i> , 2003, 140, 73-77.	1.0	35
107	Expression profiling targeting chromosomes for tumor classification and prediction of clinical behavior. <i>Genes Chromosomes and Cancer</i> , 2003, 38, 207-214.	2.8	18
108	Role of gain of 12p in germ cell tumour development. <i>Apmis</i> , 2003, 111, 161-170.	2.0	126

#	ARTICLE	IF	CITATIONS
109	Loss of 13q14-q21 and Gain of 5p14-pter in the Progression of Leiomyosarcoma. <i>Modern Pathology</i> , 2003, 16, 778-785.	5.5	27
110	Chromosome 1q expression profiling and relapse in Wilms' tumour. <i>Lancet, The</i> , 2002, 360, 385-386.	13.7	57
111	Mediastinal synovial sarcoma: report of two cases with molecular genetic analysis. <i>Annals of Thoracic Surgery</i> , 2002, 73, 628-630.	1.3	39
112	Identification of amplified and expressed genes in breast cancer by comparative hybridization onto microarrays of randomly selected cDNA clones. <i>Genes Chromosomes and Cancer</i> , 2002, 34, 104-114.	2.8	66
113	Unusual case of leukemic mantle cell lymphoma with amplified CCND1/IGH fusion gene. <i>Genes Chromosomes and Cancer</i> , 2002, 33, 206-212.	2.8	31
114	The SYT-SSX1 fusion type of synovial sarcoma is associated with increased expression of cyclin A and D1. A link between t(X;18)(p11.2; q11.2) and the cell cycle machinery. <i>Oncogene</i> , 2002, 21, 5791-5796.	5.9	42
115	Mutations of the BRAF gene in human cancer. <i>Nature</i> , 2002, 417, 949-954.	27.8	9,374
116	Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. <i>Cancer Research</i> , 2002, 62, 135-40.	0.9	390
117	Gain of 1q Is Associated with Adverse Outcome in Favorable Histology Wilms' Tumors. <i>American Journal of Pathology</i> , 2001, 158, 393-398.	3.8	127
118	Characterization of chromosome aberrations associated with soft-tissue leiomyosarcomas by twenty-four-color karyotyping and comparative genomic hybridization analysis. <i>Genes Chromosomes and Cancer</i> , 2001, 31, 54-64.	2.8	55
119	Disruption of the ATM gene in breast cancer. <i>Cancer Genetics and Cytogenetics</i> , 2001, 126, 97-101.	1.0	14
120	Definition of chromosome aberrations in testicular germ cell tumor cell lines by 24-color karyotyping and complementary molecular cytogenetic analyses. <i>Cancer Genetics and Cytogenetics</i> , 2001, 128, 120-129.	1.0	25
121	Characterization of chromosome 1 abnormalities in malignant melanomas. , 2000, 28, 121-125.		69
122	A novel and consistent amplicon at 13q31 associated with alveolar rhabdomyosarcoma. , 2000, 28, 220-226.		75
123	Evaluation of 24-color multifluor-fluorescence in-situ hybridization (M-FISH) karyotyping by comparison with reverse chromosome painting of the human breast cancer cell line T-47D. <i>Chromosome Research</i> , 2000, 8, 127-132.	2.2	18
124	Genes, chromosomes, and rhabdomyosarcoma. <i>Genes Chromosomes and Cancer</i> , 1999, 26, 275-285.	2.8	145
125	Synovial sarcoma specific translocation associated with both epithelial and spindle cell components. , 1999, 82, 605-608.		32
126	Dual colour fluorescence in situ hybridization to paraffin-embedded samples to deduce the presence of the der(X)t(X;18)(p11.2;q11.2) and involvement of either the SSX1 or SSX2 gene: a diagnostic and prognostic aid for synovial sarcoma. , 1999, 187, 490-496.		55

#	ARTICLE	IF	CITATIONS
127	Chromosome 3 imbalances are the most frequent aberration found in non-small cell lung carcinoma. <i>Lung Cancer</i> , 1999, 23, 61-66.	2.0	30
128	Cloning and Mapping of Members of the MYM Family. <i>Genomics</i> , 1999, 60, 244-247.	2.9	28
129	Poorly Differentiated Synovial Sarcoma. <i>American Journal of Surgical Pathology</i> , 1999, 23, 106-112.	3.7	209
130	Chromosome translocations in sarcomas and the analysis of paraffin-embedded material. , 1998, 184, 1-3.		9
131	Characterization of a t(8;13)(p11;q11-12) in an atypical myeloproliferative disorder. <i>Genes Chromosomes and Cancer</i> , 1998, 21, 70-73.	2.8	14
132	cDNA Cloning of a Third Human C2-Domain-Containing Class II Phosphoinositide 3-Kinase, PI3K-C2 ³ , and Chromosomal Assignment of This Gene (PIK3C2G) to 12p12. <i>Genomics</i> , 1998, 54, 569-574.	2.9	57
133	Establishing Germ Cell Origin of Undifferentiated Tumors by Identifying Gain of 12p Material Using Comparative Genomic Hybridization Analysis of Paraffin-Embedded Samples. <i>Diagnostic Molecular Pathology</i> , 1998, 7, 260-266.	2.1	39
134	Identification and cDNA Cloning of a Novel Mammalian C2 Domain-Containing Phosphoinositide 3-Kinase, HsC2-PI3K. <i>Biochemical and Biophysical Research Communications</i> , 1997, 233, 537-544.	2.1	64
135	Characterisation and chromosome mapping of the human non receptor tyrosine kinase gene, brk. <i>Oncogene</i> , 1997, 15, 1497-1502.	5.9	44
136	Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. <i>Oncogene</i> , 1997, 15, 2233-2239.	5.9	298
137	Phyllodes tumors of the breast analyzed by comparative genomic hybridization and association of increased 1q copy number with stromal overgrowth and recurrence. <i>Genes Chromosomes and Cancer</i> , 1997, 20, 275-281.	2.8	59
138	Primitive Neuroectodermal Tumor of the Kidney Confirmed by Fluorescence In Situ Hybridization. <i>American Journal of Surgical Pathology</i> , 1997, 21, 461-468.	3.7	56
139	Characterisation of a human serine hydroxymethyltransferase pseudogene and its localisation to 1p32.3â€“33. <i>Human Genetics</i> , 1996, 97, 340-344.	3.8	10
140	REVIEW ARTICLE. THE MOLECULAR PATHOLOGY OF SMALL ROUND-CELL TUMOURSâ€™ RELEVANCE TO DIAGNOSIS, PROGNOSIS, AND CLASSIFICATION. <i>Journal of Pathology</i> , 1996, 178, 116-121.	4.5	68
141	INTERPHASE FLUORESCENCE IN SITU HYBRIDIZATION DETECTION OF t(2;13)(q35;q14) IN ALVEOLAR RHABDOMYOSARCOMAâ€™ A DIAGNOSTIC TOOL IN MINIMALLY INVASIVE BIOPSIES. , 1996, 178, 410-414.		44
142	Loss of the chromosomal region 5q11-q31 in the myeloid cell line HL-60: Characterization by comparative genomic hybridization and fluorescence in situ hybridization. , 1996, 15, 182-186.		14
143	Novel formation and amplification of the PAX7-FKHR fusion gene in a case of alveolar rhabdomyosarcoma. , 1996, 17, 7-13.		50
144	Recent advances in the diagnosis, prognosis and classification of childhood solid tumours. <i>British Medical Bulletin</i> , 1996, 52, 724-741.	6.9	7

#	ARTICLE	IF	CITATIONS
145	INTERPHASE FLUORESCENCE IN SITU HYBRIDIZATION DETECTION OF t(2;13)(q35;q14) IN ALVEOLAR RHABDOMYOSARCOMA—A DIAGNOSTIC TOOL IN MINIMALLY INVASIVE BIOPSIES. <i>Journal of Pathology</i> , 1996, 178, 410-414.	4.5	2
146	Characterisation of a human serine hydroxymethyltransferase pseudogene and its localisation to 1p32.3-33. <i>Human Genetics</i> , 1996, 97, 340-344.	3.8	0
147	Characterization of a t(10; 11) (p13-14; q14-21) in the monoblastic cell line U937. <i>Genes Chromosomes and Cancer</i> , 1995, 13, 138-142.	2.8	8
148	Diagnosis of Ewing's sarcoma and related tumours by detection of chromosome 22q12 translocations using fluorescence in situ hybridization on tumour touch imprints. <i>Journal of Pathology</i> , 1995, 176, 137-142.	4.5	40
149	Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. <i>Nature Genetics</i> , 1994, 7, 502-508.	21.4	723
150	The molecular biology of soft tissue sarcomas. <i>European Journal of Cancer</i> , 1993, 29, 2054-2058.	2.8	12